Switching to aflibercept in patients with diabetic macular edema who had a poor response to ranibizumab led to positive results in a prospective study.
Fifty eyes of 40 patients were analyzed. Previous Lucentis (ranibizumab, Genentech) treatment duration was 30 months on average, during which a mean of 21 injections had been administered. In the 6 months before the study, patients had received five or six injections. The results of Eylea (aflibercept, Bayer) were evaluated at 20 weeks, after the patients had received five monthly injections.
Positive results were obtained, with (Read more...)
Uncategorized